EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent and anticipated novel drug approvals (4Q 2024 through 3Q 2025)

Matthew H Rim, Collin Dean, Enela Aliaj, Matthew Dandino, Tara Tanriverdi, Andrew M Levitsky

American Journal of Health-System Pharmacy · 2025

DOI: 10.1093/ajhp/zxae352 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Health-System Pharmacy, 2025. Verfasst von Matthew H Rim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern Medicine, Chicago, IL, USA. Hauptthemen laut MEDLINE: Drug Approval, Pharmacists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals. Summary Selected drug approvals anticipated in the 12-month period covering the fourth quarter of 2024 through the third quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from among 51 novel drugs awaiting US Food and Drug Administration approval. New drugs for severe rare diseases, cancers, autoimmune diseases, acute pain, and reversal of anticoagulation are being developed. Additionally, a new cell therapy for treatment of graft-versus-host disease joined the group of novel targeted therapies for various diseases awaiting approval.

Conclusion

Novel therapies for treating rare diseases and cancers continue to strengthen the current drug pipeline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalPharmacistsHumansUnited StatesUnited States Food and Drug AdministrationProfessional RoleRare Diseases

Stichwörter der Autor:innen

Food and Drug Administration drug approvalclinical trialsdrug approval processinvestigational drugsmedication developmentnew drug approvals

Autor:innen und Institutionen

  • Northwestern Medicine, Chicago, IL, USA.
  • IPD Analytics, Aventura, FL, USA.

Zitieren

APA

Rim, M. H., Dean, C., Aliaj, E., Dandino, M., Tanriverdi, T., & Levitsky, A. M. (2025). Recent and anticipated novel drug approvals (4Q 2024 through 3Q 2025). American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxae352

Vancouver

Rim MH, Dean C, Aliaj E, Dandino M, Tanriverdi T, Levitsky AM. Recent and anticipated novel drug approvals (4Q 2024 through 3Q 2025). American Journal of Health-System Pharmacy. 2025. doi:10.1093/ajhp/zxae352

BibTeX
@article{Rim2025,
  author = {Rim, Matthew H and Dean, Collin and Aliaj, Enela and Dandino, Matthew and Tanriverdi, Tara and Levitsky, Andrew M},
  title = {Recent and anticipated novel drug approvals (4Q 2024 through 3Q 2025)},
  journal = {American Journal of Health-System Pharmacy},
  year = {2025},
  doi = {10.1093/ajhp/zxae352}
}
Kostenlos starten →